AR003131A1 - Preparados de liberacion controlada en multiples particulas a base de una sal potasica alcalinizante activa adecuado para producir una forma farmaceuticaoral y comprimidos obtenidos. - Google Patents
Preparados de liberacion controlada en multiples particulas a base de una sal potasica alcalinizante activa adecuado para producir una forma farmaceuticaoral y comprimidos obtenidos.Info
- Publication number
- AR003131A1 AR003131A1 ARP960102873A AR10287396A AR003131A1 AR 003131 A1 AR003131 A1 AR 003131A1 AR P960102873 A ARP960102873 A AR P960102873A AR 10287396 A AR10287396 A AR 10287396A AR 003131 A1 AR003131 A1 AR 003131A1
- Authority
- AR
- Argentina
- Prior art keywords
- controlled release
- potassium
- crystals
- alkalinizing
- salt
- Prior art date
Links
- 239000002245 particle Substances 0.000 title abstract 4
- 150000003839 salts Chemical class 0.000 title abstract 3
- 238000013270 controlled release Methods 0.000 title 1
- 239000013078 crystal Substances 0.000 abstract 4
- 230000003113 alkalizing effect Effects 0.000 abstract 3
- 239000003405 delayed action preparation Substances 0.000 abstract 2
- 239000002552 dosage form Substances 0.000 abstract 2
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 abstract 2
- 208000020084 Bone disease Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000011248 coating agent Substances 0.000 abstract 1
- 238000000576 coating method Methods 0.000 abstract 1
- 230000003412 degenerative effect Effects 0.000 abstract 1
- 230000002209 hydrophobic effect Effects 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 239000012528 membrane Substances 0.000 abstract 1
- 229910052700 potassium Inorganic materials 0.000 abstract 1
- 239000011591 potassium Substances 0.000 abstract 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 abstract 1
- 235000015497 potassium bicarbonate Nutrition 0.000 abstract 1
- 239000011736 potassium bicarbonate Substances 0.000 abstract 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 abstract 1
- 238000009138 potassium supplementation Methods 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/10—Carbonates; Bicarbonates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5015—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Preparados de liberación controlada en múltiples partículas que incorporan una sal alcalinizante de potasio, con preferencia bicarbonato potásico, comoingrediente activo, que son adecuados para obtener formas de dosificación farmacéuticaspara administración oral. Dichas formas de dosificación sonútiles para la suplementación de potasio y para el tratamiento de enfermedades degenerativas de los huesos o enfermedades cardiovasculares, por ejemplo,osteoporosis e hipertensión. Dichoprepara do de liberación controlada comprende (a) una multiplicidad de monocristales de la sal alcalinizante de potasio,teniendo los cristales relaciones de aspecto inferiores a 3:1, tamano de partículas superior a 500 micrones, un tamanomedio de par tículas en pesosuperior a 700 micrones y un área superficial B.E.T. inferior a 0,015 m2/g (b) un revestimiento sobre cada uno de los cristales de sal alcalinizante de salalcalinizante de potasio que comprende un material formador depelícula y una cera hidrófoba compatibles, siendo ambos insolubles en agua, solubles en elmismo disolvente miscibles entre sí y forman una membrana permeable fuerte. Los cristales revestidos pueden conformarse en tabletas.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/472,693 US5674529A (en) | 1995-06-06 | 1995-06-06 | Alkalinizing potassium salt controlled release preparations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR003131A1 true AR003131A1 (es) | 1998-07-08 |
Family
ID=23876566
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP960102873A AR003131A1 (es) | 1995-06-06 | 1996-06-03 | Preparados de liberacion controlada en multiples particulas a base de una sal potasica alcalinizante activa adecuado para producir una forma farmaceuticaoral y comprimidos obtenidos. |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US5674529A (es) |
| EP (1) | EP0840598A4 (es) |
| JP (1) | JPH11506778A (es) |
| KR (1) | KR19990022537A (es) |
| CN (1) | CN1106837C (es) |
| AR (1) | AR003131A1 (es) |
| AU (1) | AU698784B2 (es) |
| BR (1) | BR9608392A (es) |
| CA (1) | CA2223281A1 (es) |
| CO (1) | CO4700033A1 (es) |
| CZ (1) | CZ288129B6 (es) |
| HU (1) | HUP9900856A2 (es) |
| NO (1) | NO312815B1 (es) |
| NZ (1) | NZ310138A (es) |
| PL (1) | PL323939A1 (es) |
| SK (1) | SK167797A3 (es) |
| WO (1) | WO1996039127A1 (es) |
| ZA (1) | ZA964427B (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4759099A (en) * | 1998-09-21 | 2000-03-23 | Mcneil-Ppc, Inc. | Heat stable antacid and antigas suspensions |
| US20030157247A1 (en) * | 2000-06-14 | 2003-08-21 | Yoshiro Chikami | Method for producing coated bioactive granule |
| US8101209B2 (en) | 2001-10-09 | 2012-01-24 | Flamel Technologies | Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles |
| US20030190343A1 (en) * | 2002-03-05 | 2003-10-09 | Pfizer Inc. | Palatable pharmaceutical compositions for companion animals |
| FR2837100B1 (fr) * | 2002-03-18 | 2004-07-23 | Flamel Tech Sa | Comprimes a bases de microcapsules a liberation modifiee |
| EP1492511B3 (fr) | 2002-04-09 | 2012-05-02 | Flamel Technologies | Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee de principe(s) actif(s) |
| ES2314227T7 (es) | 2002-04-09 | 2012-11-19 | Flamel Technologies | Formulacion farmaceutica oral en forma de suspension acuosa de microcapsulas que permiten la liberacion modificada de amoxilicina. |
| FR2838647B1 (fr) * | 2002-04-23 | 2006-02-17 | Particules enrobees a liberation prolongee, leur procede de preparation et comprimes les contenant | |
| US20040109889A1 (en) * | 2002-12-04 | 2004-06-10 | Bunick Frank J. | Surface treatment composition for soft substrates |
| WO2004091614A2 (en) * | 2003-04-14 | 2004-10-28 | Teva Pharmaceutical Industries Ltd. | Stabilized amlodipine maleate formations |
| CA2702152A1 (en) * | 2007-10-12 | 2009-04-16 | Haijun Xu | Process for the manufacture of a pharmaceutical product |
| FR2967578B1 (fr) * | 2010-11-18 | 2012-12-28 | Advicenne Pharma | Composition pharmaceutique comportant des sels de citrate et de bicarbonate, et son utilisation pour le traitement de la cystinurie |
| WO2025128724A1 (en) * | 2023-12-12 | 2025-06-19 | Arbert, Llc | Coated inorganic salts and uses thereof |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3538214A (en) * | 1969-04-22 | 1970-11-03 | Merck & Co Inc | Controlled release medicinal tablets |
| US4140756A (en) * | 1976-06-10 | 1979-02-20 | Mead Johnson & Company | Film-coated matrix core tablet |
| US4259315A (en) * | 1980-06-13 | 1981-03-31 | A. H. Robins Company, Inc. | Controlled release potassium dosage form |
| DK151608C (da) * | 1982-08-13 | 1988-06-20 | Benzon As Alfred | Fremgangsmaade til fremstilling af et farmaceutisk peroralt polydepotpraeparat med kontrolleret afgivelse |
| DK152744C (da) * | 1982-08-13 | 1988-10-31 | Benzon As Alfred | Fremgangsmaade til fremstilling af et farmaceutisk peroralt polydepotpraeparat |
| WO1985003436A1 (en) * | 1984-02-10 | 1985-08-15 | A/S Alfred Benzon | Diffusion coated multiple-units dosage form |
| DK62184D0 (da) * | 1984-02-10 | 1984-02-10 | Benzon As Alfred | Diffusionsovertrukket polydepotpraeparat |
| CH658188A5 (de) * | 1984-03-23 | 1986-10-31 | Ciba Geigy Ag | Lagerstabile schnellzerfallende pharmazeutische presslinge. |
| US4863743A (en) * | 1985-02-19 | 1989-09-05 | Key Pharmaceuticals, Inc. | Controlled release potassium chloride |
| GB8519310D0 (en) * | 1985-07-31 | 1985-09-04 | Zyma Sa | Granular active substances |
| GB8702411D0 (en) * | 1987-02-03 | 1987-03-11 | Zyma Sa | Swellable pellets |
| US4822619A (en) * | 1987-02-18 | 1989-04-18 | Ionor, Inc. | Controlled release pharmaceutical preparation containing a gastrointestinal irritant drug |
| US5035898A (en) * | 1987-11-27 | 1991-07-30 | Schering Corporation | Potassium/magnesium supplement |
| US5171583A (en) * | 1988-10-21 | 1992-12-15 | The Regents Of The University Of California | Treatment of osteoporosis using potassium bicarbonate |
| WO1990004402A1 (en) * | 1988-10-21 | 1990-05-03 | The Regents Of The University Of California | Treatment of osteoporosis |
| US5498428A (en) * | 1988-10-21 | 1996-03-12 | The Regents Of The University Of California | Treatment of hypertension by oral administration of potassium bicarbonate |
| DE3838094A1 (de) * | 1988-11-10 | 1990-05-17 | Nordmark Arzneimittel Gmbh | Feste pharmazeutische retardform |
| US5077051A (en) * | 1990-04-10 | 1991-12-31 | Warner-Lambert Company | Sustained release of active agents from bioadhesive microcapsules |
| US5445805A (en) * | 1993-05-06 | 1995-08-29 | Church & Dwight Co., Inc. | Large potassium bicarbonate crystals and process for the preparation thereof |
-
1995
- 1995-06-06 US US08/472,693 patent/US5674529A/en not_active Expired - Lifetime
-
1996
- 1996-05-30 ZA ZA9604427A patent/ZA964427B/xx unknown
- 1996-06-03 AR ARP960102873A patent/AR003131A1/es not_active Application Discontinuation
- 1996-06-06 CO CO96029255A patent/CO4700033A1/es unknown
- 1996-06-06 HU HU9900856A patent/HUP9900856A2/hu unknown
- 1996-06-06 AU AU60473/96A patent/AU698784B2/en not_active Ceased
- 1996-06-06 EP EP96918140A patent/EP0840598A4/en not_active Withdrawn
- 1996-06-06 JP JP9501435A patent/JPH11506778A/ja not_active Ceased
- 1996-06-06 BR BR9608392-1A patent/BR9608392A/pt not_active IP Right Cessation
- 1996-06-06 KR KR1019970709018A patent/KR19990022537A/ko not_active Ceased
- 1996-06-06 CA CA002223281A patent/CA2223281A1/en not_active Abandoned
- 1996-06-06 NZ NZ310138A patent/NZ310138A/en unknown
- 1996-06-06 WO PCT/US1996/009016 patent/WO1996039127A1/en not_active Ceased
- 1996-06-06 SK SK1677-97A patent/SK167797A3/sk unknown
- 1996-06-06 PL PL96323939A patent/PL323939A1/xx unknown
- 1996-06-06 CN CN96194592A patent/CN1106837C/zh not_active Expired - Fee Related
- 1996-06-06 CZ CZ19973892A patent/CZ288129B6/cs not_active IP Right Cessation
-
1997
- 1997-12-03 NO NO19975567A patent/NO312815B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| EP0840598A4 (en) | 2001-08-29 |
| NO312815B1 (no) | 2002-07-08 |
| CZ288129B6 (cs) | 2001-04-11 |
| ZA964427B (en) | 1997-02-24 |
| CO4700033A1 (es) | 1998-12-29 |
| HUP9900856A2 (hu) | 1999-08-30 |
| EP0840598A1 (en) | 1998-05-13 |
| NZ310138A (en) | 1999-04-29 |
| PL323939A1 (en) | 1998-04-27 |
| BR9608392A (pt) | 1999-11-30 |
| US5674529A (en) | 1997-10-07 |
| AU698784B2 (en) | 1998-11-05 |
| SK167797A3 (en) | 1998-06-03 |
| NO975567D0 (no) | 1997-12-03 |
| CN1106837C (zh) | 2003-04-30 |
| CZ389297A3 (cs) | 1998-06-17 |
| WO1996039127A1 (en) | 1996-12-12 |
| NO975567L (no) | 1998-02-05 |
| JPH11506778A (ja) | 1999-06-15 |
| CN1187121A (zh) | 1998-07-08 |
| AU6047396A (en) | 1996-12-24 |
| CA2223281A1 (en) | 1996-12-12 |
| KR19990022537A (ko) | 1999-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2199981T3 (es) | Modo de preparacion de formulaciones farmaceuticas de particulas finas. | |
| ES2527225T3 (es) | Forma de dosificación oral sólida que contiene nanopartículas y proceso para su formulación utilizando gelatina de pescado | |
| AR003131A1 (es) | Preparados de liberacion controlada en multiples particulas a base de una sal potasica alcalinizante activa adecuado para producir una forma farmaceuticaoral y comprimidos obtenidos. | |
| ES2255103T3 (es) | Sistema osmotico de administracion de dosis en forma soluble. | |
| US6238705B1 (en) | Bioerodible porous compositions | |
| EP1001748B1 (en) | A process for the preparation of a granulate suitable to the preparation of rapidly disintegrable mouth-soluble tablets | |
| KR100352881B1 (ko) | 소수성물질의제약학적인고체제형을제조하는방법 | |
| AU592363B2 (en) | Controlled release tablet | |
| ES2761407T3 (es) | Forma de dosificación rápidamente dispersable de topiramato | |
| ES2260068T3 (es) | Preparacion en forma de lamina para la liberacion bifasica de sustancias farmacologicamente activas u otras. | |
| US20080317863A1 (en) | Pharmaceutical Compositions Useful in the Transmucosal Administration of Drugs | |
| ES2539268T3 (es) | Pastilla blanda que contiene celulósicos de peso molecular alto | |
| AR066313A2 (es) | Una formulacion de liberacion controlada de galantamina, una forma farmaceutica de dosificacion, un proceso para la preparacion de dicha formulacion, y el uso de dicha formulacion para la manufactura de un medicamento | |
| WO2008127669A1 (en) | Bilayer lyophilized pharmaceutical compositions and methods of making and using same | |
| ES2924195T3 (es) | Gránulos de principio activo con doble enmascaramiento del sabor, su procedimiento de preparación y comprimidos bucodispersables que los contienen | |
| DE69909316D1 (de) | Pharmazeutische formulierung mit omeprazol | |
| CO5160287A1 (es) | Formulacion de liberacion controlada de divalproex sodico | |
| JP3844517B2 (ja) | 作用物質の放出が調節された、フルピルチン又はその生理学的に認容性の塩を含有する医薬製剤及びその製法 | |
| DE69816951D1 (de) | Zubereitung enthaltend Cefaclor oder Cephalexin mit modifizierter Freisetzungsmatrix | |
| JP2006503855A (ja) | 難溶性活性成分を含む速放性の投与形態 | |
| CA2481848A1 (en) | Active ingredient particles carrying clopidogrel or a salt thereof, their use and method of preparation | |
| JP2015028030A (ja) | 凍結乾燥薬学的組成物、及びその製造及び使用方法 | |
| NO965381D0 (no) | Pellets | |
| CA2000932A1 (en) | Oral pharmaceutical controlled release multiple unit dosage form | |
| JP2010254691A (ja) | コーティングされた凍結乾燥成型品 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |